 Featured Content |
Optimizing Survival in Advanced Prostate Cancer
A Sanofi Oncology–sponsored symposium
By: Bertrand Tombal, Belgium (Chair); Stйphane Oudard, France; and Fred Saad, Canada
In this symposium, held during the 34th Congress of the SIU in Glasgow, Scotland, Prof. Tombal, Prof. Saad and Prof. Oudard offer a complete description of the changing scenario in the treatment of castration-resistant prostate cancer (CRPC) and hormone-naïve M+ prostate cancer.
 |
The incorporation of cabazitaxel, and the new hormones abiraterone and enzalutamida, opened new perspectives in the treatment of CRPC, with most registration trials showing a 20% to 30% reduction in the risk of death. The different randomized control trials, including the combination of different agents targeting the androgen receptor and exploring the gene sequencing, are critically assessed.
In summary, this symposium provides a complete update on the changes and challenges of advanced prostate cancer treatment. |
Click here to view a short clip of this symposium. To watch the whole symposium and for more webcasts from the SIU 2014 Congress:
To watch the whole symposium and for more:
 |
Log on to SIU Academy |
 |
Click the SIU 2014 Congress banner in the What's Trending tab |
Accessing SIU Academy
Online: Haven't signed up for SIU Academy yet? Register for full access to SIU Academy by clicking here. SIU members can use their existing username and password to access the site. Forgot your password? Please click here.
Via your mobile device: Visit the Talks on the Go and the Poster on the GO websites for more information on how to download the "Talks on the Go" and the “Poster on the Go“ apps from your tablet or cell phone and log in using your username and password.
|
